- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
A New Era in PAH Treatment?
An expert on pulmonary arterial hypertension discusses the potential impact of emerging therapies, including sotatercept, ralinepag, and inhaled imatinib.
EP: 1.Evolving Guidelines for PAH Treatment
EP: 2.New Therapeutic Frontiers in PAH
EP: 3.Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management
EP: 4.Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension
EP: 5.Breaking Down the PAH Cost Burden
EP: 6.A New Era in PAH Treatment?
EP: 7.Clinical Evidence for Emerging PAH Therapies
EP: 8.Integrating New PAH Therapies into Clinical Practice
EP: 9.Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes
EP: 10.FDA Approves Sotatercept for Pulmonary Arterial Hypertension
EP: 11.Overcoming Barriers to Better Patient Outcomes in PAH
EP: 12.Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches
EP: 13.Optimizing PAH Care Delivery for Better Outcomes
EP: 14.Addressing Unmet Needs in the PAH Landscape
Video content above is prompted by the following question:
- What is your assessment of the potential clinical impact of new or emerging pulmonary arterial hypertension (PAH) therapies, such as sotatercept, ralinepag, and inhaled imatinib, in terms of reducing hospitalizations or need for supportive care and improving long-term patient outcomes and quality of life?
New Study Evaluates Quality-of-Life Instruments for Patients With PAH
December 12th 2024A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that although several instruments demonstrate strong psychometric properties and reliability, significant gaps remain in these tools' validation and methodological rigor.
Read More
Nanoparticle Delivery Holds Promise for Treatment of PAH
December 8th 2024Aerosolized vascular endothelial growth factor/stromal cell-derived factor-1α (VEGFNP/SDFNP) led to a lower pulmonary arterial pressure and prevented right ventricular hypertrophy after monocrotaline (MCT) injection in rats.
Read More
